子宮頸癌市場－全球及區域分析：按國家/地區分類－分析與預測（2025-2035）

Cervical Cancer Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

出版日期: 2025年11月18日 | 出版商:

BIS Research | 英文 90 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄圖表

全球子宮頸癌市場分析與預測（2025-2035）

子宮頸癌是一種惡性腫瘤，它起源於子宮頸，即子宮下部狹窄的部分，與陰道相連。

它主要由持續感染高危險型人類乳突病毒（HPV）引起，這種病毒性行為感染。此疾病會經歷癌前病變（子宮頸上皮內瘤變）並發展為侵襲性癌，主要是鱗狀細胞癌或腺癌。

子宮頸癌負擔日益加重是推動市場成長的主要因素之一。子宮頸癌是全球女性第四大常見癌症，世界衛生組織（世衛組織）報告稱，2020年全球新增病例約60.4萬例，死亡病例約34.2萬例。此疾病對中低收入國家（LMICs）的影響尤其嚴重，約90%的子宮頸癌相關死亡病例發生在這些國家。這主要是由於篩檢項目不足和人類乳突病毒(HPV)疫苗疫苗接種覆蓋率有限。在全球範圍內，持續感染高危險型人類乳突病毒（HPV）16型和18型約佔子宮頸癌病例的70%。

免疫查核點抑制劑的核准和廣泛應用徹底改變了復發性或轉移性子宮頸癌的治療模式。這些治療方法提高了患者的存活率，並為傳統化療提供了替代方案，尤其是在晚期疾病的治療中，推動了市場顯著成長。

此外，擴大人類乳突病毒(HPV)疫苗計劃將減輕未來的治療負擔。雖然人類乳突病毒(HPV)疫苗具有預防作用，但其全球推廣將透過降低子宮頸癌的發生率，對治療市場產生直接影響。這促使製藥公司投資於涵蓋預防、診斷和治療的綜合性子宮頸癌產品組合。例如，全球疫苗宣傳活動正在加速人類乳突病毒(HPV)疫苗在低收入和中等收入國家（LMIC）的推廣，並透過將重點轉向晚期治療和精準醫療，影響製藥市場的長期趨勢。

然而，新型免疫療法和標靶治療的高成本限制了其可及性，尤其是在疾病負擔最重的低收入和中等收入國家（LMICs）。醫保報銷難題、醫療基礎設施匱乏以及病患的經濟承受能力阻礙了這些療法的廣泛應用。此外，子宮頸癌的分子異質性以及對化療和免疫療法等治療手段不斷演變的抗藥性機制也帶來了持續的挑戰。因此，亟需持續的藥物研發和合併治療策略，以提高療效並克服抗藥性。

製藥公司正積極探索將化療與化療、標靶治療藥物和放射線治療相結合，旨在改善臨床療效並延長無惡化生存期。這些治療方法在臨床開發平臺中佔有越來越重要的地位。此外，分子診斷技術的進步使得生物標記指導治療成為可能，從而最佳化了PD-L1抑制劑等治療方案的患者選擇，並提高了治療反應率。這正推動市場朝精準腫瘤學方向發展。

子宮頸癌市場競爭異常激烈，由擁有涵蓋免疫療法、標靶治療和預防性疫苗等全面產品組合的大型製藥企業主導。製藥公司與國際衛生組織之間的合作進一步加劇了這種競爭格局，旨在提高中低收入國家的疫苗接種覆蓋率和治療可及性。然而，監管的複雜性、價格壓力以及即將到期的專利到期都帶來了挑戰，推動製藥公司持續創新和策略性市場擴張。在創新、價格可負擔性和整合全球夥伴關係方面表現卓越的公司，最有能力引領這個不斷發展的子宮頸癌市場。

Cervical cancer is a malignant tumor arising from the cervix, the lower, narrow end of the uterus that connects to the vagina. It is primarily caused by persistent infection with high-risk types of human papillomavirus (HPV), a sexually transmitted virus. The disease progresses through precancerous lesions (cervical intraepithelial neoplasia) before developing into invasive cancer, primarily squamous cell carcinoma or adenocarcinoma.

The increasing burden of cervical cancer is one of the major factors driving the market growth. Cervical cancer ranks as the fourth most prevalent cancer among women worldwide, with the World Health Organization (WHO) reporting approximately 604,000 new cases and 342,000 deaths in 2020. The disease disproportionately affects low- and middle-income countries (LMICs), which bear nearly 90% of cervical cancer-related mortality, largely due to inadequate screening programs and limited access to HPV vaccination. Globally, persistent infection with high-risk human papillomavirus (HPV) types 16 and 18 is responsible for about 70% of cervical cancer cases.

The approval and increasing use of immune checkpoint inhibitors, have revolutionized the treatment landscape for recurrent or metastatic cervical cancer. These therapies offer improved survival benefits and are driving significant market growth by providing alternatives to traditional chemotherapy, particularly in advanced disease stages.

Moreover, the expansion of HPV vaccination programs will reduce future treatment burden. While HPV vaccines are preventive, their increasing global adoption directly impacts the therapeutic market by reducing the incidence of cervical cancer over time. This has encouraged pharmaceutical companies to invest in comprehensive cervical cancer portfolios spanning prevention, diagnostics, and treatment. For instance, global vaccination campaigns have accelerated HPV vaccine uptake in LMICs, influencing long-term drug market dynamics by shifting focus toward advanced-stage therapies and precision medicine.

However, the high cost of novel immunotherapies and targeted agents limits their accessibility, particularly in LMICs where the disease burden is highest. Reimbursement challenges, lack of healthcare infrastructure, and patient affordability constrain widespread adoption. In addition, cervical cancer's molecular heterogeneity and evolving resistance mechanisms to therapies like chemotherapy and immunotherapy pose ongoing challenges. This necessitates continuous drug development and combination strategies to enhance efficacy and overcome resistance.

Pharmaceutical companies are actively exploring combinations of immunotherapies with chemotherapy, targeted agents, and radiotherapy to improve clinical outcomes and extend progression-free survival. These regimens represent a growing segment in clinical development pipelines. Moreover, advances in molecular diagnostics are enabling biomarker-guided therapies, improving patient selection for treatments such as PD-L1 inhibitors and enhancing response rates, thus driving the market toward precision oncology.

The cervical cancer market is highly competitive, dominated by major pharmaceutical companies with comprehensive portfolios spanning immunotherapies, targeted treatments, and preventive vaccines. The competitive environment is further shaped by collaborations between pharmaceutical companies and global health organizations to enhance vaccine coverage and access to therapies in low- and middle-income countries. However, regulatory complexities, pricing pressures, and upcoming patent expirations pose challenges that drive ongoing innovation and strategic market expansion. Companies that excel in integrating innovation, affordability, and global partnerships are best positioned to lead in this evolving cervical cancer market.

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Cervical Cancer Market: Industry Outlook

1.1 Market Overview
1.2 Epidemiological Analysis of Cervical Cancer, By Region
1.3 Regulatory Landscape
1.4 Key Trends
1.5 Clinical Trial Analysis
1.6 Market Dynamics
- 1.6.1 Impact Analysis
- 1.6.2 Market Drivers
- 1.6.3 Market Restraint
- 1.6.4 Market Opportunities

2. Global Cervical Cancer Market, by Region, $Million, 2023-2035

2.1 North America
- 2.1.1 Market Dynamics
- 2.1.2 Market Sizing and Forecast
  - 2.1.2.1 North America Cervical Cancer Market, by Country
    - 2.1.2.1.1 U.S.
2.2 Europe
- 2.2.1 Market Dynamics
- 2.2.2 Market Sizing and Forecast
  - 2.2.2.1 Europe Cervical Cancer Market, by Country
    - 2.2.2.1.1 Germany
    - 2.2.2.1.2 U.K.
    - 2.2.2.1.3 France
    - 2.2.2.1.4 Italy
    - 2.2.2.1.5 Spain
2.3 Asia-Pacific
- 2.3.1 Market Dynamics
- 2.3.2 Market Sizing and Forecast
  - 2.3.2.1 Asia-Pacific Cervical Cancer Market, by Country
    - 2.3.2.1.1 Japan

3. Global Cervical Cancer Market: Competitive Landscape and Company Profiles

3.1 Competitive Landscape
- 3.1.1 Key Strategies and Developments, by Company
  - 3.1.1.1 Funding Activities
  - 3.1.1.2 Mergers and Acquisitions
  - 3.1.1.3 Regulatory Approvals
  - 3.1.1.4 Partnerships, Collaborations, and Business Expansions
3.2 Company Profiles
- 3.2.1 Pfizer Inc.
  - 3.2.1.1 Overview
  - 3.2.1.2 Top Products / Product Portfolio
  - 3.2.1.3 Top Competitors
  - 3.2.1.4 Target Customers/End-Users
  - 3.2.1.5 Key Personnel
  - 3.2.1.6 Analyst View
- 3.2.2 Merck & Co., Inc
  - 3.2.2.1 Overview
  - 3.2.2.2 Top Products / Product Portfolio
  - 3.2.2.3 Top Competitors
  - 3.2.2.4 Target Customers/End-Users
  - 3.2.2.5 Key Personnel
  - 3.2.2.6 Analyst View
- 3.2.3 F. Hoffmann-La Roche Ltd
  - 3.2.3.1 Overview
  - 3.2.3.2 Top Products / Product Portfolio
  - 3.2.3.3 Top Competitors
  - 3.2.3.4 Target Customers/End-Users
  - 3.2.3.5 Key Personnel
  - 3.2.3.6 Analyst View
- 3.2.4 Bristol-Myers Squibb Company
  - 3.2.4.1 Overview
  - 3.2.4.2 Top Products / Product Portfolio
  - 3.2.4.3 Top Competitors
  - 3.2.4.4 Target Customers/End-Users
  - 3.2.4.5 Key Personnel
  - 3.2.4.6 Analyst View
- 3.2.5 Corbus Pharmaceuticals Holdings, Inc
  - 3.2.5.1 Overview
  - 3.2.5.2 Top Products / Product Portfolio
  - 3.2.5.3 Top Competitors
  - 3.2.5.4 Target Customers/End-Users
  - 3.2.5.5 Key Personnel
  - 3.2.5.6 Analyst View
- 3.2.6 Others